Imaging Biomarker in Cancer Drug Induced ILD (ImageILD)

European Organisation for Research and Treatment of Cancer (EORTC)

Status

Unknown

Conditions

Drug Induced Interstitial Lung Disease (DIILD) Cancer Patients

Treatments

Other: Thoracic CT

Other: Clinical evaluations

Study type

Interventional

Funder types

NETWORK

Identifiers

NCT03294746

EORTC-1658-IG

Details and patient eligibility

About

Drug induced interstitial lung disease (DIILD) is caused by iatrogenic injury to the lung parenchyma and can be caused by over four hundred different drugs in humans. Diagnosing DIILD is a challenge for clinicians and radiologists as a positive diagnosis depends on exclusion of other causes including respiratory infection, occupational, recreational, and environmental exposures, specific respiratory disorders, and systemic diseases.

The aim of this study is to qualify an objective CT scoring system for DIILD assessment. In addition, the quantitative information obtained from CT scans with densitometry and texture analysis will be explored.

Enrollment

70 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥ 18 years
World health organization (WHO) performance status 0-2
Life expectancy > 6 months
Proven cancer diagnosis in a patient actively undergoing anti-cancer therapy
New onset symptoms (e.g. cough, fever, dyspnoea, and hypoxia) at any time during or within 4 weeks of the last dose of anti-cancer treatment
New onset radiological (CXR or CT) abnormalities within the lungs at any time during or within 4 weeks of the last dose of anti-cancer treatment (e.g. diffuse lung changes, infiltrative opacification in the periphery of the lung or ground glass changes) with a locally reviewed diagnosis of DIILD as the most likely explanation for the radiological abnormalities.
Treatment for DIILD planned (e.g. drug withdrawal, interruption +/- supportive therapy including corticosteroids, oxygen, bronchodilators etc.). Concomitant treatment with antibiotics, anticoagulants etc. is permitted pending results of investigations for differential diagnoses.
Able to undergo pulmonary function tests (at a minimum spirometry and gas transfer (DLCO))
Patients enrolled on other anti-cancer investigational trials are permitted at investigator discretion
Informed written consent obtained according to national/local regulations
Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test within 14 days before study registration

Exclusion criteria

Clinically suspected or confirmed radiological features of any malignancy involving the lungs at the time of study registration
Claustrophobia, or inability to undergo non-contrast CT examination
Known or suspected non-drug related ILD (e.g. lung abnormalities due to other causes such as occupational exposure)
Previous extensive thoracic surgery (e.g. lobectomy)
Clinical, radiological or microbiological evidence of active lower respiratory tract infection
Currently active, clinically significant heart disease, such as uncontrolled class 3 or 4 congestive heart failure defined by the New York Heart Association Functional Classification
Any medical, psychological, sociological or geographical condition that could affect participation in the study and compliance with the study protocol